

Julien Dumurgier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8172525/publications.pdf>

Version: 2024-02-01

117
papers

4,496
citations

94433

37
h-index

123424

61
g-index

126
all docs

126
docs citations

126
times ranked

6180
citing authors

#	ARTICLE	IF	CITATIONS
1	Slow walking speed and cardiovascular death in well functioning older adults: prospective cohort study. <i>BMJ: British Medical Journal</i> , 2009, 339, b4460-b4460.	2.3	274
2	Association of sleep duration in middle and old age with incidence of dementia. <i>Nature Communications</i> , 2021, 12, 2289.	12.8	254
3	Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. <i>JAMA Neurology</i> , 2021, 78, 1471.	9.0	204
4	Risk of cardiovascular disease morbidity and mortality in frail and pre-frail older adults: Results from a meta-analysis and exploratory meta-regression analysis. <i>Ageing Research Reviews</i> , 2017, 35, 63-73.	10.9	182
5	Alcohol consumption and risk of dementia: 23 year follow-up of Whitehall II cohort study. <i>BMJ: British Medical Journal</i> , 2018, 362, k2927.	2.3	150
6	Social inequalities in multimorbidity, frailty, disability, and transitions to mortality: a 24-year follow-up of the Whitehall II cohort study. <i>Lancet Public Health</i> , The, 2020, 5, e42-e50.	10.0	147
7	Oxidative stress increases BACE1 protein levels through activation of the PKR-eIF2 γ pathway. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012, 1822, 885-896.	3.8	139
8	Association Between Age at Diabetes Onset and Subsequent Risk of Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1640.	7.4	135
9	Prevalence of amyloid β pathology in distinct variants of primary progressive aphasia. <i>Annals of Neurology</i> , 2018, 84, 729-740.	5.3	132
10	The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 41.	6.2	121
11	Association of ideal cardiovascular health at age 50 with incidence of dementia: 25 year follow-up of Whitehall II cohort study. <i>BMJ: British Medical Journal</i> , 2019, 366, 14414.	2.3	117
12	Contribution to Alzheimer's disease risk of rare variants in TREM2, SORL1, and ABCA7 in 1779 cases and 1273 controls. <i>Neurobiology of Aging</i> , 2017, 59, 220.e1-220.e9.	3.1	116
13	Cerebrospinal fluid amyloid β 42/40 ratio in clinical setting of memory centers: a multicentric study. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 30.	6.2	101
14	SORL1 rare variants: a major risk factor for familial early-onset Alzheimer's disease. <i>Molecular Psychiatry</i> , 2016, 21, 831-836.	7.9	96
15	Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly. <i>Neurology</i> , 2016, 87, 920-926.	1.1	86
16	Seizures in dominantly inherited Alzheimer disease. <i>Neurology</i> , 2016, 87, 912-919.	1.1	81
17	Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis. <i>Alzheimer's and Dementia</i> , 2021, 17, 755-767.	0.8	81
18	Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1451-1459.	2.6	80

#	ARTICLE	IF	CITATIONS
19	Increased levels of cerebrospinal fluid JNK3 associated with amyloid pathology: links to cognitive decline. <i>Journal of Psychiatry and Neuroscience</i> , 2015, 40, 151-161.	2.4	75
20	Gait Speed and Decline in Gait Speed as Predictors of Incident Dementia. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2017, 72, glw110.	3.6	74
21	Hypertension and lower walking speed in the elderly: the Three-City study. <i>Journal of Hypertension</i> , 2010, 28, 1506-1514.	0.5	73
22	Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting. <i>Alzheimer's and Dementia</i> , 2013, 9, 406-413.	0.8	63
23	MRI atrophy of the caudate nucleus and slower walking speed in the elderly. <i>NeuroImage</i> , 2012, 60, 871-878.	4.2	62
24	The association of APOE ϵ 4 with cognitive function over the adult life course and incidence of dementia: 20-year follow-up of the Whitehall II study. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 5.	6.2	60
25	Relevance of A β 42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLMR Scale. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 138.	3.4	59
26	Impact of harmonization of collection tubes on Alzheimer's disease diagnosis. , 2014, 10, S390-S394.e2.		58
27	Impact of cerebro-spinal fluid biomarkers of Alzheimer's disease in clinical practice: a multicentric study. <i>Journal of Neurology</i> , 2014, 261, 144-151.	3.6	56
28	Restless legs syndrome is frequently overlooked in patients being evaluated for polyneuropathies. <i>European Journal of Neurology</i> , 2007, 14, 788-792.	3.3	54
29	Associations between baseline amyloid, sex, and APOE on subsequent tau accumulation in cerebrospinal fluid. <i>Neurobiology of Aging</i> , 2019, 78, 178-185.	3.1	54
30	Increased Cerebrospinal Fluid Levels of Double-Stranded RNA-Dependant Protein Kinase in Alzheimer's Disease. <i>Biological Psychiatry</i> , 2012, 71, 829-835.	1.3	52
31	PKR involvement in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 83.	6.2	52
32	Impact of the 2008-2012 French Alzheimer Plan on the Use of Cerebrospinal Fluid Biomarkers in Research Memory Center: The PLM Study. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 297-305.	2.6	51
33	Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease. <i>Neurology</i> , 2020, 95, e953-e961.	1.1	50
34	Motor function in the elderly. <i>Neurology</i> , 2013, 81, 417-426.	1.1	48
35	Cerebrospinal Fluid PKR Level Predicts Cognitive Decline in Alzheimer's Disease. <i>PLoS ONE</i> , 2013, 8, e53587.	2.5	46
36	Epidemiology of neurological diseases in older adults. <i>Revue Neurologique</i> , 2020, 176, 642-648.	1.5	45

#	ARTICLE	IF	CITATIONS
37	Sex differences and the role of education in cognitive ageing: analysis of two UK-based prospective cohort studies. <i>Lancet Public Health</i> , The, 2021, 6, e106-e115.	10.0	45
38	A diagnostic scale for Alzheimer's disease based on cerebrospinal fluid biomarker profiles. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 38.	6.2	44
39	Change in Fast Walking Speed Preceding Death: Results From a Prospective Longitudinal Cohort Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2014, 69A, 354-362.	3.6	41
40	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study. <i>PLoS Medicine</i> , 2020, 17, e1003289.	8.4	39
41	Risk prediction models for dementia: role of age and cardiometabolic risk factors. <i>BMC Medicine</i> , 2020, 18, 107.	5.5	38
42	Biomarkers and acute brain injuries: interest and limits. <i>Critical Care</i> , 2014, 18, 220.	5.8	37
43	Healthy behaviors at age 50 years and frailty at older ages in a 20-year follow-up of the UK Whitehall II cohort: A longitudinal study. <i>PLoS Medicine</i> , 2020, 17, e1003147.	8.4	34
44	Cerebrospinal fluid A beta 1-40 peptides increase in Alzheimer's disease and are highly correlated with phospho-tau in control individuals. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 123.	6.2	33
45	Inverse association between CSF A β 42 levels and years of education in mild form of Alzheimer's disease: The cognitive reserve theory. <i>Neurobiology of Disease</i> , 2010, 40, 456-459.	4.4	30
46	Cognitive function after several years of antiretroviral therapy with stable central nervous system penetration score. <i>HIV Medicine</i> , 2013, 14, 311-315.	2.2	29
47	Association between kidney function and incidence of dementia: 10-year follow-up of the Whitehall II cohort study. <i>Age and Ageing</i> , 2022, 51, .	1.6	29
48	Primary Progressive Aphasia in the Network of French Alzheimer Plan Memory Centers. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1459-1471.	2.6	28
49	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , 2022, 18, 1868-1879.	0.8	26
50	A Novel ELISA for the Measurement of Cerebrospinal Fluid SNAP-25 in Patients with Alzheimer's Disease. <i>Neuroscience</i> , 2019, 420, 136-144.	2.3	25
51	Differential Diagnosis of Dementia with High Levels of Cerebrospinal Fluid Tau Protein. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 905-913.	2.6	21
52	CSF A β 1-42 Levels and Glucose Metabolism in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 845-851.	2.6	20
53	Lipid-Lowering Drugs Associated With Slower Motor Decline in the Elderly Adults. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2014, 69A, 199-206.	3.6	20
54	CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 88.	6.2	20

#	ARTICLE	IF	CITATIONS
55	Emotional memory enhancement in respect of positive visual stimuli in Alzheimer's disease emerges after rich and deep encoding. <i>Cortex</i> , 2015, 65, 89-101.	2.4	19
56	CSF level of β -amyloid peptide predicts mortality in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 29.	6.2	19
57	Utility of CSF biomarkers in psychiatric disorders: a national multicentre prospective study. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 27.	6.2	18
58	Biomarker profiles of Alzheimer's disease and dynamic of the association between cerebrospinal fluid levels of β -amyloid peptide and tau. <i>PLoS ONE</i> , 2019, 14, e0217026.	2.5	18
59	What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France. <i>BMJ Open</i> , 2019, 9, e026380.	1.9	17
60	Terminal decline in objective and self-reported measures of motor function before death: 10 year follow-up of Whitehall II cohort study. <i>BMJ</i> , 2021, 374, n1743.	6.0	17
61	Hyperuricemia, Gout, and the Brain: an Update. <i>Current Rheumatology Reports</i> , 2021, 23, 82.	4.7	17
62	How many patients are eligible for disease-modifying treatment in Alzheimer's disease? A French national observational study over 5 years. <i>BMJ Open</i> , 2019, 9, e029663.	1.9	16
63	Impact of recommendations on the initial therapy of Parkinson's disease: A population-based study in France. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 543-546.	2.2	14
64	Exacerbated CSF abnormalities in younger patients with Alzheimer's disease. <i>Neurobiology of Disease</i> , 2013, 54, 486-491.	4.4	14
65	Diagnosis associated with Tau higher than 1200 pg/mL: Insights from the clinical and laboratory practice. <i>Clinica Chimica Acta</i> , 2019, 495, 451-456.	1.1	13
66	Timeline of pain before dementia diagnosis: a 27-year follow-up study. <i>Pain</i> , 2021, 162, 1578-1585.	4.2	13
67	Time Orientation and 10 Years Risk of Dementia in Elderly Adults: The Three-City Study. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 1411-1418.	2.6	12
68	Plasma neuregulin 1 as a synaptic biomarker in Alzheimer's disease: a discovery cohort study. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	6.2	12
69	The screening of Alzheimer's patients with CSF biomarkers, modulates the distribution of APOE genotype: impact on clinical trials. <i>Journal of Neurology</i> , 2014, 261, 1187-1195.	3.6	11
70	Blood-Based Kinase Assessments in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 338.	3.4	11
71	Association of APOE ϵ 4 with cerebral gray matter volumes in non-demented older adults: The MEMENTO cohort study. <i>NeuroImage</i> , 2022, 250, 118966.	4.2	11
72	Pro-Apoptotic Kinase Levels in Cerebrospinal Fluid as Potential Future Biomarkers in Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2015, 6, 168.	2.4	10

#	ARTICLE	IF	CITATIONS
73	The role of attention in emotional memory enhancement in pathological and healthy aging. Journal of Clinical and Experimental Neuropsychology, 2016, 38, 434-454.	1.3	10
74	Increased Cerebrospinal Fluid Tau Levels in Logopenic Variant of Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 39, 611-616.	2.6	9
75	Distribution of Cerebrospinal Fluid Biomarker Profiles in Patients Explored for Cognitive Disorders. Journal of Alzheimer's Disease, 2018, 64, 889-897.	2.6	9
76	Cerebrospinal Fluid and Plasma Biomarkers do not Differ in the Presenile and Late-Onset Behavioral Variants of Frontotemporal Dementia. Journal of Alzheimer's Disease, 2020, 74, 903-911.	2.6	9
77	New highly sensitive rodent and human tests for soluble amyloid precursor protein alpha quantification: preclinical and clinical applications in Alzheimer's disease. BMC Neuroscience, 2012, 13, 84.	1.9	8
78	Frontotemporal dementia is the leading cause of $\Delta^{24}/T+$ profiles defined with $\Delta^{24}/40$ ratio. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 161-169.	2.4	8
79	[¹⁸ F]FDG PET may differentiate cerebral amyloid angiopathy from Alzheimer's disease. European Journal of Neurology, 2021, 28, 1511-1519.	3.3	8
80	Cerebrospinal Fluid Biomarkers in Patients With Alcohol Use Disorder and Persistent Cognitive Impairment. Alcoholism: Clinical and Experimental Research, 2021, 45, 561-565.	2.4	8
81	A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging. Neurology, 2022, 99, .	1.1	8
82	Muscle magnetic resonance imaging sensitivity does not decrease in chronic, mild, or proximal lower limb neuropathies. Muscle and Nerve, 2012, 45, 659-667.	2.2	7
83	Screening for cognitive and affective dysfunction in patients suspected of mild cognitive impairment. International Journal of Geriatric Psychiatry, 2014, 29, 936-942.	2.7	7
84	Full-length and C-terminal neurogranin in Alzheimer's disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays. Alzheimer's Research and Therapy, 2020, 12, 168.	6.2	7
85	Neurofilaments as Emerging Biomarkers of Neuroaxonal Damage to Differentiate Behavioral Frontotemporal Dementia from Primary Psychiatric Disorders: A Systematic Review. Diagnostics, 2021, 11, 754.	2.6	7
86	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's and Dementia, 2021, 17, .	0.8	7
87	Relationship between blood pressure, cognitive function and education level in elderly patients with diabetes: A preliminary study. Diabetes and Metabolism, 2013, 39, 418-423.	2.9	6
88	Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers. Current Alzheimer Research, 2018, 15, 691-700.	1.4	5
89	Brain Glucose Metabolism in Cerebral Amyloid Angiopathy. Stroke, 2021, 52, 1478-1482.	2.0	3
90	Telemedicine in French Memory Clinics During the COVID-19 Pandemic. Journal of Alzheimer's Disease, 2022, 86, 525-530.	2.6	3

#	ARTICLE	IF	CITATIONS
91	IC-P-162: Entorhinal, parahippocampal, and inferior temporal F18-T807 SUVR correlates with CSF total tau and tau T181P in cognitively normal elderly. , 2015, 11, P109-P109.		2
92	Gait Decline. Hypertension, 2015, 66, 263-264.	2.7	2
93	O2â€05â€01: CEREBROSPINAL FLUID SYNAPTIC VESICLE GLYCOPROTEIN 2A IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P545.	0.8	2
94	Clinical features related to CSF level of amyloid AÎ²42 and AÎ²40 proteins in presence of lobar microbleeds. Revue Neurologique, 2020, 176, 864-867.	1.5	2
95	Comparison of the predictive accuracy of multiple definitions of cognitive impairment for incident dementia: a 20-year follow-up of the Whitehall II cohort study. The Lancet Healthy Longevity, 2021, 2, e407-e416.	4.6	2
96	O4-01-04: Entorhinal, parahippocampal, and inferior temporal F18-T807 SUVR correlates with CSF total tau and tau T181P in cognitively normal elderly. , 2015, 11, P267-P267.		1
97	The Diagnostic Value of a Short Memory Test: The TNI-93. Journal of Alzheimer's Disease, 2021, , 1-11.	2.6	1
98	Biomarqueurs du liquide cÃ©rÃ©brospinal dans la maladie d'Alzheimer. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 307-320.	0.0	1
99	P1-129: CSF AD BIOMARKERS IN MEMORY CLINIC PATIENTS: THE EP.L.M.FR STUDY. , 2014, 10, P347-P347.		0
100	O1-09-01: IMPACT OF CEREBROSPINAL FLUID BIOMARKERS OF ALZHEIMER'S DISEASE IN CLINICAL PRACTICE: A MULTICENTRIC STUDY. , 2014, 10, P146-P147.		0
101	P2-113: CSF AMYLOID-Î² 42/40 RATIO IN CLINICAL SETTINGS: A MULTICENTRIC STUDY. , 2014, 10, P512-P512.		0
102	CSF levels of the BACE1 substrate Neuregulin1 correlate with cognition and synaptic biomarkers in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e037097.	0.8	0
103	Memory assessment in illiterate patients: The diagnostic value of the TNI 93. Alzheimer's and Dementia, 2020, 16, e042059.	0.8	0
104	Current status and quantitative results of the AMYPAD prognostic and natural history study. Alzheimer's and Dementia, 2020, 16, e044711.	0.8	0
105	Current status and quantitative results of the AMYPAD prognostic and natural history study. Alzheimer's and Dementia, 2021, 17, .	0.8	0
106	Title is missing!. , 2020, 17, e1003289.		0
107	Title is missing!. , 2020, 17, e1003289.		0
108	Title is missing!. , 2020, 17, e1003289.		0

#	ARTICLE	IF	CITATIONS
109	Title is missing!. , 2020, 17, e1003289.		0
110	Title is missing!. , 2020, 17, e1003289.		0
111	Title is missing!. , 2020, 17, e1003289.		0
112	Title is missing!. , 2020, 17, e1003289.		0
113	Title is missing!. , 2020, 17, e1003147.		0
114	Title is missing!. , 2020, 17, e1003147.		0
115	Title is missing!. , 2020, 17, e1003147.		0
116	Title is missing!. , 2020, 17, e1003147.		0
117	Title is missing!. , 2020, 17, e1003147.		0